Monte Rosa Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $23,194 | $84,929 | $60,647 | $9,216 |
Gross Profit | 21,069 | 84,929 | 56,483 | 9,216 |
EBITDA | -15,554 | 46,084 | 15,065 | -24,424 |
EBIT | -17,679 | 44,036 | 13,004 | -26,527 |
Net Income | -12,295 | 46,885 | 13,437 | -23,859 |
Net Change In Cash | 23,194 | 84,929 | 60,647 | 9,216 |
Free Cash Flow | -36,415 | -47,079 | 128,739 | -21,393 |
Cash | 69,429 | 78,530 | 224,254 | 125,575 |
Basic Shares | 82,186 | 82,956 | 61,436 | 82,011 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $75,622 | $0 | $0 | $0 |
Gross Profit | 67,501 | -6,222 | -8,559 | -2,132 |
EBITDA | -72,991 | -137,089 | -108,639 | -70,750 |
EBIT | -81,112 | -143,311 | -112,384 | -72,882 |
Net Income | -72,700 | -135,352 | -108,501 | -73,958 |
Net Change In Cash | 75,622 | 0 | 0 | 0 |
Cost of Revenue | -291,219 | 308,546 | ||
Free Cash Flow | 38,008 | -62,843 | -105,377 | -69,095 |
Cash | 224,254 | 128,101 | 54,912 | 346,071 |
Basic Shares | 73,910 | 51,396 | 47,227 | 46,535 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.35 |
2025-03-31 | $0.57 |
2024-12-31 | -$0.35 |
